Navigation Links
Vaporized viral vector shows promise in anti-cancer gene therapy
Date:6/8/2009

A new lung cancer therapy employing a vaporized viral vector to deliver a cancer-inhibiting molecule directly to lung tissue shows early promise in mouse trials, according to researchers at the Ministry of Education, Science and Technology in Korea.

Gene therapy is an area of great promise, but delivery mechanisms, which have included intravenous injection and intratracheal instillation, have proven problematic for effective delivery of genetic therapy to lung tissues.

"Aerosol delivery targets the lungs specifically and represents a noninvasive alternative for targeting genes to the lung," wrote Myung-Haing Cho, D.V.M., Ph.D., professor at Seoul National University and principal investigator of the study. "The delivery of genes via aerosol holds promise for the treatment of a broad spectrum of pulmonary disorders and offers numerous advantages over more invasive modes of delivery."

The results of Dr. Cho's promising research will be published in the June 15 issue of the American Journal of Respiratory and Critical Care Medicine.

Lung cancer is the most common cause of cancer deaths worldwide, killing more people each year than breast, prostate and colon cancers combined. It costs the U.S. alone more than $9 billion a year, according to the Centers for Disease Control and Prevention. Most available therapiessurgery, radiation and chemotherapyoffer transient relief at best and are typically ineffective in advanced stages of the disease. For this reason, novel therapies for lung cancer are of great interest.

Dr. Cho and colleagues targeted the Akt signaling pathway, which has been shown to be an important regulator of cell proliferation and cancer progression. A recent report found that 90 percent of non-small cell lung carcinomas were associated with the activation of the Akt signaling pathway. They chose a lentiviral vector, derived from a retrovirus and known for its ability to infect nondividing cells and e
'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Pill box organizers increase HIV patients adherence and improve viral suppression
2. DNA damage response confers a barrier for viral tumorigenesis
3. Key Viral Change Could Help Bird Flu Spread
4. Antiviral Wont Improve Bells Palsy Outcome
5. Mayo Clinic Proceedings article explores possible link between obesity and viral infections
6. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
7. American Medical Association Clears Path for Adenoviral Conjunctivitis - Pink Eye - Detector
8. Antivirals reduce deaths from flu in hospitalized patients
9. MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study
10. Antiretroviral Drugs May Prevent Vaginal Transmission of HIV
11. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Gene variant predicts medication response in patients with alcohol dependence 2Health News:Gene variant predicts medication response in patients with alcohol dependence 3Health News:New Natural Energy Bar Hits the Road with Dieters & Athletes Alike 2Health News:Lower-income neighborhoods associated with higher obesity rates 2Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 2Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 3Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 4Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 5Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 6Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 7Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 8Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 9Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 10Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 11Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 12Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 13Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 14Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 15Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 16Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 17Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 18Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 19Health News:Parsons Announces Start of Wi-Fi Service on Fauntleroy/Vashon/Southworth Ferry Run 2
Breaking Medicine Technology:Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 2Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 3Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 4New Executive Leadership and CEO Announced for BiPar Sciences 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Stroke Doubles Risk of Hip Thigh Fractures 53889 1Stroke Doubles Risk of Hip Thigh Fractures 53889 2Stroke Doubles Risk of Hip Thigh Fractures 53889 3One of the Nation 26apos 3Bs Leading Analytical Testing Laboratories is Now Easier to Access Pace Analytical Launches New Web Site to Showcase Its 13424 1One of the Nation 26apos 3Bs Leading Analytical Testing Laboratories is Now Easier to Access Pace Analytical Launches New Web Site to Showcase Its 13424 2Partnership for Prescription Assistance Prepared to Help New Jersey Workers Hurt by Recession 53885 1Partnership for Prescription Assistance Prepared to Help New Jersey Workers Hurt by Recession 53885 2Partnership for Prescription Assistance Prepared to Help New Jersey Workers Hurt by Recession 53885 3Partnership for Prescription Assistance Prepared to Help New Jersey Workers Hurt by Recession 53885 4